Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds
October 02, 2023 12:53 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the entry...
Checkpoint Therapeutics to Participate in the Cantor Global Healthcare Conference
September 21, 2023 08:30 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that...
Checkpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023 08:30 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that...
Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
August 14, 2023 16:15 ET
|
Checkpoint Therapeutics, Inc
Biologics License Application for cosibelimab under review by U.S. FDA; Successful mid-cycle meeting with U.S. FDA completed; PDUFA goal date of January 3, 2024 Longer-term cosibelimab results...
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market
July 31, 2023 08:00 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it...
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell Carcinoma
July 27, 2023 07:00 ET
|
Checkpoint Therapeutics, Inc
55% objective response rate; 23% complete response rate in locally advanced cSCC 50% objective response rate; 13% complete response rate in metastatic cSCC Cosibelimab continues to demonstrate a...
Checkpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing
June 28, 2023 08:00 ET
|
Checkpoint Therapeutics, Inc
Results support comparability of cosibelimab 800 mg every-two-week and 1200 mg every-three-week dosing regimens Biologics License Application for cosibelimab under review by U.S. FDA; PDUFA goal date...
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
May 23, 2023 08:30 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it...
Checkpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
May 15, 2023 16:15 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial...
Checkpoint Therapeutics Announces $6.1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
March 31, 2023 08:00 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it...